

PUBLIKATIONSLISTE

Originalarbeiten

1. Schütte K, Zimmermann L, Bornschein J, **Csepregi A**, Rühl R, Ricke J, Malfertheiner P. Sorafenib therapy in patients with advanced hepatocellular carcinoma in advanced liver cirrhosis. 2011 Digestion; 83:275-82.
2. Manns MP, Woynarowski M, Kreisel W, **Csepregi A**, ... et al. European AIH-BUC-Study Group. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 2010; 139:1198-206.
3. Papp Maria, Altörjai I, Vitalis Zs, ... **Csepregi A**, Mannose-binding lectin deficiency confers risk for bacterial infections in a large Hungarian cohort of patients with liver cirrhosis. J Hepatol 2010; 53:484-91.
4. **Csepregi A**, Ebert MP, Röcken C, et al. Promoter methylation of CDKN2A and the lack of p16 expression characterize patients with hepatocellular carcinoma. BMC Cancer 2010; 10:317.
5. Neumann H, **Csepregi A**, Evert M, Malfertheiner P. Citalopram-induced acute liver toxicity. J Clin Psychopharmacol 2008; 28(2):254-5.
6. **Csepregi A**, Röcken C, Hoffmann J, Müller O, Kutzner N, Ping G, Schneider-Stock R, Roessner A, Malfertheiner P, Ebert MP. Promoter methylation and protein expression of the APC gene in hepatocellular carcinoma. J Cancer Res Clin Oncol 2008; 134:579-89.
7. **Csepregi A**, Rickes S, Dombrowski F, Malfertheiner P. Incidental finding of multiple hyperechoic liver lesions. J Gastroenterol Hepatol 2007; 22:759.

8. Bohr URM, Kuester D, Meyer F, Wex T, Stillert M, **Csepregi A**, et al. Prevalence of Helicobacteraceae in gallstone disease and gallbladder carcinoma in the German population. *Clin Microbiol Infect* 2007; 13:525-31.
9. Neumann H, **Csepregi A**, Sailer M, Malfertheiner P. Glatiramer acetate induced autoimmune hepatitis in a patients with multiple sclerosis. *J Neurol* 2007; 254:816-7.
10. Ebert MPA, Model F, Mooney S, Hale K, Lograsso J, Tonnes-Priddy L, **Csepregi A**, Röcken C, Schulz H-U, Malfertheiner P, Lofton-Day C. Aristaless-like homeobox-4 gene methylation is a potential marker for colorectal adenocarcinomas. *Gastroenterology* 2006; 131:1418-30.
11. Rickes S, Vopel A, Klauck S, **Csepregi A**, Wolle K, Peitz U, et al. Impact of operators experience on value of high-resolution transabdominal ultrasound in the diagnosis of choledocholithiasis: A prospective comparison using endoscopic retrograde cholangiography as gold standard. *Scand J Gastroenterol* 2006; 41:838-43.
12. **Csepregi A**, Röcken C, Treiber G, Malfertheiner P. Budesonide induces complete remission in autoimmune hepatitis. *World J Gastroenterol* 2006; 12:1362-6.
13. **Csepregi A**, Treiber G, Röcken C, Malfertheiner P. Twinrix□ induced severe jaundice as the first manifestation of autoimmune hepatitis. *World J Gastroenterol* 2005; 11:4114-6.
14. Rickes S, **Csepregi A**. Hepatobiliary and pancreatic: Budd-Chiari syndrome. *J Gastroenterol Hepatol* 2004; 19:828.
15. Kalabay L, Nemesánszky E, **Csepregi A**, Pusztay M, David K, Horvath G, et al. Paradoxical alteration of acute-phase protein levels in patients with chronic hepatitis C treated with IFN-alpha2b. *Int Immunol* 2004; 16:51-4.
16. **Csepregi A**, Poór Gy, Nemesánszky E. Rheumatoid arthritis und hepatitis C virus: further pieces to the puzzle. *J Rheumatol* 2004; 31:1016-7.
17. Biró A, Horváth A, Varga L, Nemesánszky E, **Csepregi A**, Dávid K, et al. Serum anti-cholesterol antibodies in chronic hepatitis-C patients during IFN-α-2b treatment. *Immunobiology* 2003; 207:161-8.
18. **Csepregi A**, Strassburg CP, Kneip S, Kayser A, Nemesánszky E, Szalay F, Obermayer-Straub P, Manns MP. Evidence for a lipoyl domain-independent B cell autoepitope mapped to human branched-chain acyltransferase in primary biliary cirrhosis. *Clin Develop Immunol* 2003; 10:173-82.

19. **Csepregi** A, Szodoray P, Zeher M. Do autoantibodies predict autoimmune liver disease in primary Sjögren's syndrome? Data of 180 patients upon a five-year follow-up. *Scand J Immunol* 2002; 56:623-9.
20. **Csepregi** A, Nemesánszky E, Lüttig B, Obermayer-Straub P, Manns M. LKM3 autoantibodies in hepatitis C cirrhosis: A further phenomenon of the HCV-induced autoimmunity. *Hepatitis Review Journal* 2002; 1:20-1.
21. Szodoray P, **Csepregi** A, Héjjas M, Horányi M, Zeher M. Sicca syndrome with or without hepatitis C virus infection: report on data of 213 consecutive patients. *Rheumatol Int* 2001; 21:6-9.
22. Firneisz G, Lakatos PL, Hungarian Viral Hepatitis Study Group (...**Csepregi** A,...) and Szalay F. Serum dipeptidyl peptidase IV (DPP IV, CD26) activity in chronic hepatitis C. *Scand J Gastroenterol* 2001; 36:877-80.
23. **Csepregi** A, Nemesánszky E, Lüttig B, Obermayer-Straub P, Manns MP. LKM3 autoantibodies in hepatitis C cirrhosis: a further phenomenon of the HCV-induced autoimmunity. *Am J Gastroenterol* 2001; 96:910-1.
24. Biró L, Varga L, Nemesánszky E, ... **Csepregi** A. C5b-9 and interleukin-6 in chronic hepatitis C: Surrogate markers predicting short-term response to interferon alfa-2b. *Scand J Gastroenterol* 2000; 35:1092-6.
25. **Csepregi** A, Nemesánszky E. Acquired C1 esterase inhibitor deficiency (letter). *Ann Intern Med* 2000; 133:837-9.
26. Nemesánszky E, Pusztay M, **Csepregi** A. Effects of interferon treatment on the carbohydrate metabolism of patients with chronic hepatitis C. *Eur J Intern Med* 2000; 11:151-5.
27. Bíró L, Varga L, Pár A, Nemesánszky E, **Csepregi** A, Telegdy L, et al. Changes in the acute phase complement component and IL-6 levels in patients with chronic hepatitis C receiving interferon alpha-2b. *Immunol Lett* 2000; 72:69-74.
28. Horváth-Karajz K, **Csepregi** A, Nemesánszky E, Tulassay Z, Selmecci L, Szalay F. Activity of neutral endopeptidase in patients with primary biliary cirrhosis. *Orv Hetil* 2000; 141:963-5.
29. **Csepregi** A, Nemesánszky E. Acute cholestatic liver injury caused by azathioprine in early rheumatoid arthritis (letter). *J Clin Rheumatol* 2000; 6:112-3.
30. **Csepregi** A, Nemesánszky E. Mitochondrial autoantibodies to the components of 2-oxoacid dehydrogenase complex are early markers of primary biliary cirrhosis (letter). *J Clin Rheumatol* 2000; 6:109-10.

31. **Csepregi A**, Rojkovich B, Nemesánszky E, Poór Gy, Horányi M, Héjjas M. Chronic seropositive polyarthritis linked to hepatitis B virus: Report of two cases and review of the literature. *Magyar Rheumatol* 2000; 41:35-43.
32. **Csepregi A**, Rojkovich B, Héjjas M, Horányi M, Nemesánszky E, Poór Gy. Chronic seropositive polyarthritis associated with hepatitis B virus-induced chronic liver disease: a sequel of virus persistence. *Arthritis Rheum* 2000; 43:232-3.
33. **Csepregi A**, Nemesánszky E, Farkas H, Pár A, Varga L, Füst G. Acquired C inhibitor deficiency and angioedema: A further extrahepatic manifestation of chronic hepatitis C. *Magyar Rheumatol* 1999; 40:205-9.
34. Pár A, Telegdy L, Gógl Á, Müller É (coordinators),..., **Csepregi A**, et al. Treatment for chronic viral hepatitis in Hungary. *Orv Hetil* 1999; 140:1227-34.
35. Fehér J, Lengyel G, Bálint T,..., **Csepregi A**, et al. The efficacy of combined interferon-alfa-2b and ribavirin therapy in patients with chronic hepatitis C. Interim report in 100 patients. *Orv Hetil* 1999; 140:1235-8.
36. Haba T, Nemesánszky E, **Csepregi A**, Gödény M, Szilvási I, Dabasi G, Rumi Gy. Carcinoid tumor with multiple metastases – Diagnostic difficulties and therapeutic possibilities. *Lege Artis Medicinae* 1999; 9:286-92.
37. Farkas H, **Csepregi A**, Nemesánszky E, Pár A, Gyeney L, Varga L, Füst G. Acquired angioedema associated with chronic hepatitis C. *J Allergy Clin Immunol* 1999; 103:711-2.
38. **Csepregi A**, Nemesánszky E. Cryoglobulinemia in chronic liver diseases: Cause or consequence? *Orv Hetil* 1997; 138:651-6.
39. Nemesánszky E, **Csepregi A**. Krónikus májbetegség Hepabene (Merckle) kezelésével szerzett tapasztalatok. *Gyógyszereink* 1996, 46:150-3.

Übersichtsarbeiten

1. **Csepregi A**, Malfertheiner P. Do we need alternative therapeutic options in autoimmune hepatitis. Editorial. *Curr Gastroenterol Rep* 2006; 8:177-8.
2. **Csepregi A**, Malfertheiner P. Portal hypertension. Editorial. *Dig Dis* 2005; 23:5.
3. Treiber G, **Csepregi A**, Malfertheiner P. Pathogenesis of portal hypertension. *Dig Dis* 2005; 23:6-10.
4. Nemesánszky E, **Csepregi A**. Hepatitis virus infections: Prevention and therapy. Budapest 2004, 1-41.

5. Gervain J, Nemesanszky E, **Csepregi** A. New modalities in the treatment of chronic viral hepatitis: Pegylated interferons. *Lege Artis Medicinae* 2003; 13:521-6.
6. **Csepregi** A, Nemesánszky E, Telegdy L. Szakmai ajánlások és remények a hepatitis virusfertőzések megelőzését célzó vakcinák alkalmazására. *Gyógyszereink* 2002; 52:64-8.
7. **Csepregi** A, Nemesánszky E, Rojkovich B, Poór Gy. Rheumatoid arthritis and hepatitis B virus. Evaluating the pathogenic link. *J Rheumatol* 2001; 28:474-7.
8. **Csepregi** A, Nemesánszky E, Bély M. Cryoglobulinemia in chronic liver diseases. *Z Gastroenterol* 1998; 36:391-401.
9. Nemesánszky E, **Csepregi** A. Practical considerations of immunoprophylaxis in viral hepatitis. *Orv Hetil* 1998; 139:1835-42.
10. **Csepregi** A, Nemesánszky E. Cryoglobulinemia in chronic liver diseases: Cause or consequence? *Orv Hetil* 1997; 138:651-6.
11. Nemesánszky E, **Csepregi** A, Horányi M. Hepatitis G/GB-C virus. *Magyar Belorv Arch* 1997; 50:17-22.
12. Nemesánszky E, **Csepregi** A. Hepatic lesions caused by nonsteroidal anti-inflammatory drugs (NSAIDs). *Magyar Rheumatol* 1996; 37:197-202.
13. Nemesánszky E, **Csepregi** A. H2-receptor antagonists and alcohol: clinical significance. *Orv Hetil* 1996; 137:1309-17.

Buchbeiträge

1. Nemesánszky E, **Csepregi** A. Hepatitis virusfertőzések. A megelőzés és a kezelés lehetőségei, GlaxoSmithKline, Budapest, 2001, pp. 1-20.
2. Nemesánszky E, **Csepregi** A. A gyulladásoos bélbetegségek hepatológiai vonatkozásai. In: *IBD: Válogatott fejezetek a gyulladásoos vastagbélbetegségekről*. (Főszerk. Újszászy László dr.), Medicon, Budapest, 1997, pp. 157-67.
3. Nemesánszky E, **Csepregi** A. Krónikus májbetegék interferon kezelése. (Betegtájékoztató), Budapest, 1994